In these cases, we recommend the immunohistochemical analysis of at least 3-4 in situ tissue markers [e.g., p-mTOR, p-S6, Rictor, and p-Akt (Ser473)] to provide a good representation of mTORC1 and mTORC2 activity in tumor tissue. The gene discussed is RICTOR; the disease is neoplasm.